ATE419851T1 - Verwendung von riluzol zur behandlung multipler sklerose - Google Patents

Verwendung von riluzol zur behandlung multipler sklerose

Info

Publication number
ATE419851T1
ATE419851T1 AT05001476T AT05001476T ATE419851T1 AT E419851 T1 ATE419851 T1 AT E419851T1 AT 05001476 T AT05001476 T AT 05001476T AT 05001476 T AT05001476 T AT 05001476T AT E419851 T1 ATE419851 T1 AT E419851T1
Authority
AT
Austria
Prior art keywords
riluzole
multiple sclerosis
treat multiple
treat
benzothiazolamine
Prior art date
Application number
AT05001476T
Other languages
German (de)
English (en)
Inventor
Chris Polman
Original Assignee
Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vereniging Voor Christelijk Wetenschappelijk Onderwijs filed Critical Vereniging Voor Christelijk Wetenschappelijk Onderwijs
Application granted granted Critical
Publication of ATE419851T1 publication Critical patent/ATE419851T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05001476T 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose ATE419851T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04

Publications (1)

Publication Number Publication Date
ATE419851T1 true ATE419851T1 (de) 2009-01-15

Family

ID=56290027

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05001476T ATE419851T1 (de) 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose
AT00939007T ATE287713T1 (de) 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00939007T ATE287713T1 (de) 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose

Country Status (11)

Country Link
EP (2) EP1187612B1 (https=)
JP (1) JP2003522121A (https=)
AT (2) ATE419851T1 (https=)
AU (1) AU777537B2 (https=)
CA (1) CA2375874A1 (https=)
DE (1) DE60017733T2 (https=)
ES (1) ES2235896T3 (https=)
NZ (1) NZ515685A (https=)
PT (1) PT1187612E (https=)
SI (1) SI1187612T1 (https=)
WO (1) WO2000074676A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
AU2005218625A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
MX2017006454A (es) * 2014-11-21 2018-03-23 Biohaven Pharm Holding Co Ltd Administracion sublingual de riluzol.
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
US6133258A (en) * 1995-11-05 2000-10-17 Yamanouchi Pharmaceutical Co., Ltd. Inhibitor of kainic acid neurotoxicity and pyridothiazine derivative
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
JP2003522121A (ja) 2003-07-22
ATE287713T1 (de) 2005-02-15
WO2000074676A1 (en) 2000-12-14
EP1187612B1 (en) 2005-01-26
PT1187612E (pt) 2005-05-31
AU5421900A (en) 2000-12-28
EP1552831B1 (en) 2009-01-07
DE60017733D1 (de) 2005-03-03
SI1187612T1 (en) 2005-06-30
EP1552831A1 (en) 2005-07-13
EP1187612A1 (en) 2002-03-20
NZ515685A (en) 2002-12-20
CA2375874A1 (en) 2000-12-14
AU777537B2 (en) 2004-10-21
DE60017733T2 (de) 2006-01-12
ES2235896T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE201138T1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung und prophylaxe der multiplen sclerose
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
ATE304350T1 (de) Probucol monoester zur behandlung von kreislauf- und entzündungserkrankungen
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ZA200309808B (en) Compositions and methods for the diagnosis and treatment of tumor
DE60141230D1 (de) Verwendung von Botulinum Toxin zur Behandlung von neuralgischen Schmerzen
DE60335997D1 (de) Lactoferrin-zusammensetzungen und verfahren zur behandlung von diabetischen ulcus
ATE214274T1 (de) Antikonvulsiva zur verwendung bei der behandlung von amyotropischer lateralsklerose
DE69532804D1 (de) Verwendung von hemmern des maillard-reaktion zur behandlung von krankheiten zufolge amyloidosis
ATE362374T1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69937624D1 (de) Verfahren zur Behandlung von Metalloberflächen
ATE419851T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60041365D1 (de) Verwendung von Riluzol zur Behandlung Multipler Sklerose
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
DE69827387D1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties